Chronic Pain Syndromes
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Opioid-Induced Hyperalgesia in Humans Molecular Mechanisms and Clinical Considerations
SPECIAL TOPIC SERIES Opioid-induced Hyperalgesia in Humans Molecular Mechanisms and Clinical Considerations Larry F. Chu, MD, MS (BCHM), MS (Epidemiology),* Martin S. Angst, MD,* and David Clark, MD, PhD*w treatment of acute and cancer-related pain. However, Abstract: Opioid-induced hyperalgesia (OIH) is most broadly recent evidence suggests that opioid medications may also defined as a state of nociceptive sensitization caused by exposure be useful for the treatment of chronic noncancer pain, at to opioids. The state is characterized by a paradoxical response least in the short term.3–14 whereby a patient receiving opioids for the treatment of pain Perhaps because of this new evidence, opioid may actually become more sensitive to certain painful stimuli. medications have been increasingly prescribed by primary The type of pain experienced may or may not be different from care physicians and other patient care providers for the original underlying painful condition. Although the precise chronic painful conditions.15,16 Indeed, opioids are molecular mechanism is not yet understood, it is generally among the most common medications prescribed by thought to result from neuroplastic changes in the peripheral physicians in the United States17 and accounted for 235 and central nervous systems that lead to sensitization of million prescriptions in the year 2004.18 pronociceptive pathways. OIH seems to be a distinct, definable, One of the principal factors that differentiate the use and characteristic phenomenon that may explain loss of opioid of opioids for the treatment of pain concerns the duration efficacy in some cases. Clinicians should suspect expression of of intended use. -
Aetiology of Fibrositis
Ann Rheum Dis: first published as 10.1136/ard.6.4.241 on 1 January 1947. Downloaded from AETIOLOGY OF FIBROSITIS: A REVIEW BY MAX VALENTINE From a review of systems of classification of fibrositis (National Mineral Water Hospital, Bath, 1940; Devonshire Royal Hospital, Buxton, 1940; Ministry of Health Report, 1924; Harrogate Royal Bath Hospital Report, 1940; Ray, 1934; Comroe, 1941 ; Patterson, 1938) the one in use at the National Mineral Water Hospital, Bath, is considered most valuable. There are five divisions of fibrositis as follows: (a) intramuscular, (b) periarticular, (c) bursal and tenosynovial, (d) subcutaneous, (e) perineuritic, the latter being divided into (i) brachial (ii) sciatic, etc. Laboratory Tests No biochemical abnormalities have been demonstrated in fibrositis. Mester (1941) claimed a specific test for " rheumatism ", but Copeman and Stewart (1942) did not find it of value and question its rationale. The sedimentation rate is usually normal or may be slightly increased; this is confirmed by Kahlmeter (1928), Sha;ckle (1938), and Dawson and others (1930). Miller copyright. and Gibson (1941) found a slightly increased rate in 52-3% of patients, and Collins and others (1939) found a (usually) moderately increased rate in 35% of cases tested. Case Analyses In an investigation Valentine (1943) found an incidence of fibrositis of 31-4% (60% male) at a Spa hospital. (Cf. Ministry of Health Report, 1922, 30-8%; Buxton Spa Hospital, 1940, 49 5%; Bath Spa Hospital, 1940, 22-3%; Savage, 1941, 52% in the Forces.) Fibrositis was commonest http://ard.bmj.com/ between the ages of40 and 60; this is supported by the SpaHospital Report, Buxton, 1940. -
Guidline for the Evidence-Informed Primary Care Management of Low Back Pain
Guideline for the Evidence-Informed Primary Care Management of Low Back Pain 2nd Edition These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making. Guideline Disease/Condition(s) Targeted Specifications Acute and sub-acute low back pain Chronic low back pain Acute and sub-acute sciatica/radiculopathy Chronic sciatica/radiculopathy Category Prevention Diagnosis Evaluation Management Treatment Intended Users Primary health care providers, for example: family physicians, osteopathic physicians, chiro- practors, physical therapists, occupational therapists, nurses, pharmacists, psychologists. Purpose To help Alberta clinicians make evidence-informed decisions about care of patients with non- specific low back pain. Objectives • To increase the use of evidence-informed conservative approaches to the prevention, assessment, diagnosis, and treatment in primary care patients with low back pain • To promote appropriate specialist referrals and use of diagnostic tests in patients with low back pain • To encourage patients to engage in appropriate self-care activities Target Population Adult patients 18 years or older in primary care settings. Exclusions: pregnant women; patients under the age of 18 years; diagnosis or treatment of specific causes of low back pain such as: inpatient treatments (surgical treatments); referred pain (from abdomen, kidney, ovary, pelvis, -
Enigma of Myofascial Pain-Dysfunction Syndrome - a Revisit of Review of Literature
e-ISSN: 2349-0659 p-ISSN: 2350-0964 REVIEW ARTICLE doi: 10.21276/apjhs.2018.5.1.03 Enigma of myofascial pain-dysfunction syndrome - A revisit of review of literature Abdullah Bin Nabhan* Oral and Facial Pain Specialist, Department of Dentistry, King Khalid Hospital, Al Kharj, Saudi Arabia ABSTRACT Myofascial pain-dysfunction syndrome (MPDS) is a form of myalgia that is characterized by local regions of muscle hardness that are tender and cause pain to be felt at a distance, i.e., referred pain. The central component of the syndrome is the trigger point (TrP) that is composed of a tender, taut band. Stimulation of the band, either mechanically or with activity, can produce pain. Masticatory muscle fatigue and spasm are responsible for the cardinal symptoms of pain, tenderness, clicking, and limited function that characterize the MPDS. Since MPDS covers a wide range of symptoms, it might be difficult to diagnose and provide definitive treatment. A better understanding and working knowledge of TrPs and MPDS offers an effective approach to relieve pain, restore function, and contribute significantly to patient’s quality of life. Key words: Myalgia, myofascial pain-dysfunction syndrome, referred pain, trigger points INTRODUCTION The main acceptable factors include occlusion disorders and psychological problems.[6,7-10] Muscle pain is a common problem that is underappreciated and often undertreated. Myofascial pain-dysfunction Common etiologies of MPDS may be from direct or indirect trauma, syndrome (MPDS) is a myalgic condition in which muscle and spine pathology, exposure to cumulative and repetitive strain, musculotendinous pain are the primary symptoms and is the postural dysfunction, and physical deconditioning. -
Headache and Chronic Pain in Primary Care
FAMILY PRACTICE GRAND ROUNDS Headache and Chronic Pain in Primary Care Thomas Greer, MD, MPH, Wayne Katon, MD, Noel Chrisman, PhD, Stephen Butler, MD, Dee Caplan-Tuke, MSW Seattle, W a s h in g t o n R. THOMAS GREER (Assistant Professor, Depart automobile accident while vacationing in another state Dment of Family Medicine): The management of pa and suffered multiple contusions and rib fractures. Oral tients with chronic headaches is difficult and often a source methadone had been prescribed at her second clinic visit of discord between the patient and his or her physician. when other oral narcotics failed to control her pain. She The patient with chronic headaches presented in this con also had a long history of visits for headaches, treated with ference illustrates most of the common problems encoun injections of a narcotic, usually meperidine, and oral co tered in the diagnosis, treatment, and management of pa deine. tients with other kinds of chronic pain as well. As her acute injuries healed and she was tapered off the methadone, her chronic headaches emerged as a signifi cant problem. Within a few months the patient was reg EPIDEMIOLOGY ularly requesting oral codeine for the management of her severe, intractable headaches. More than 40 million Americans consult physicians each In early September she was brought to our emergency year for complaints of headache.1 The National Ambu department by ambulance following an apparent seizure. latory Medical Care Survey, which gathered information Witnesses reported that the patient had “jerking move on approximately 90,000 patient visits to a nationally ments.” There was no incontinence; and the ambulance representative sample of physicians, determined that personnel found the patient to be irritable and disoriented headache was the second most common chronic pain but with stable vital signs. -
Clinical Data Mining Reveals Analgesic Effects of Lapatinib in Cancer Patients
www.nature.com/scientificreports OPEN Clinical data mining reveals analgesic efects of lapatinib in cancer patients Shuo Zhou1,2, Fang Zheng1,2* & Chang‑Guo Zhan1,2* Microsomal prostaglandin E2 synthase 1 (mPGES‑1) is recognized as a promising target for a next generation of anti‑infammatory drugs that are not expected to have the side efects of currently available anti‑infammatory drugs. Lapatinib, an FDA‑approved drug for cancer treatment, has recently been identifed as an mPGES‑1 inhibitor. But the efcacy of lapatinib as an analgesic remains to be evaluated. In the present clinical data mining (CDM) study, we have collected and analyzed all lapatinib‑related clinical data retrieved from clinicaltrials.gov. Our CDM utilized a meta‑analysis protocol, but the clinical data analyzed were not limited to the primary and secondary outcomes of clinical trials, unlike conventional meta‑analyses. All the pain‑related data were used to determine the numbers and odd ratios (ORs) of various forms of pain in cancer patients with lapatinib treatment. The ORs, 95% confdence intervals, and P values for the diferences in pain were calculated and the heterogeneous data across the trials were evaluated. For all forms of pain analyzed, the patients received lapatinib treatment have a reduced occurrence (OR 0.79; CI 0.70–0.89; P = 0.0002 for the overall efect). According to our CDM results, available clinical data for 12,765 patients enrolled in 20 randomized clinical trials indicate that lapatinib therapy is associated with a signifcant reduction in various forms of pain, including musculoskeletal pain, bone pain, headache, arthralgia, and pain in extremity, in cancer patients. -
AAFP Chronic Pain Toolkit
AAFP Chronic Pain Toolkit PAIN ASSESSMENT | Section 1 OVERVIEW Assessment of chronic pain should be multidimensional. Consideration should be given to several domains, including the physiological features of pain and its contributing factors, with physicians and other clinicians assessing patients for function, quality of life, mental health, and emotional health. In addition to a complete medical and medication history typically obtained at an office visit, documentation should be obtained about pain intensity, location, duration, and factors that aggravate or alleviate pain. A physical exam should include musculoskeletal and neurological components, as appropriate. Diagnostic testing and imaging may also be considered for some types of chronic pain. Many organizations, including the AAFP, recommend against imaging for low back pain within the first six weeks of treatment unless there are reasons for the imaging. These reasons may include concerns of underlying conditions, such as severe or progressive neurological deficits, or if osteomyelitis is suspected.1 Periodic reassessments of chronic pain and treatment should focus on evaluating improvements in physical health; mental and emotional health; progress towards functional treatment goals; and effectiveness and tolerability of medications for chronic pain treatment. Currently, there are no universally adopted guidelines or recommendations for assessment of chronic pain. The use of appropriate assessment tools can assist in diagnostic assessment, management, reassessment, and monitoring of treatment effects. Multiple tools are available, with many embedded in electronic health record (EHR) systems. Pain Assessment Tools The table on the next page includes selected tools for pain assessment included in this toolkit, along with links and reference to additional tools. Assessments about other relevant domains are covered in Functional and Other Assessments (Section 2). -
Pain Management in People Who Have OUD; Acute Vs. Chronic Pain
Pain Management in People Who Have OUD; Acute vs. Chronic Pain Developer: Stephen A. Wyatt, DO Medical Director, Addiction Medicine Carolinas HealthCare System Reviewer/Editor: Miriam Komaromy, MD, The ECHO Institute™ This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under contract number HHSH250201600015C. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government. Disclosures Stephen Wyatt has nothing to disclose Objectives • Understand the complexities of treating acute and chronic pain in patients with opioid use disorder (OUD). • Understand the various approaches to treating the OUD patient on an agonist medication for acute or chronic pain. • Understand how acute and chronic pain can be treated when the OUD patient is on an antagonist medication. Speaker Notes: The general Outline of the module is to first address the difficulties surrounding treating pain in the opioid dependent patient. Then to address the ways that patients with pain can be approached on either an agonist of antagonist opioid use disorder treatment. Pain and Substance Use Disorder • Potential for mutual mistrust: – Provider • drug seeking • dependency/intolerance • fear – Patient • lack of empathy • avoidance • fear Speaker Notes: It is the provider that needs to be well educated and skillful in working with this population. Through a better understanding of opioid use disorders as a disease, the prejudice surrounding the encounter with the patient may be reduced. -
Pain Management Assessment and Reassessment
North Shore-LIJ Health System is now Northwell Health System Patient Care Services POLICY TITLE: CLINICAL POLICY AND PROCEDURE Pain Management: Assessment and MANUAL Reassessment POLICY #: PCS.1603 CATEGORY SECTION: System Approval Date: 10/20/16 Effective Date: NEW Site Implementation Date: 12/2/16 Last Reviewed/Revised: NEW Prepared by: Notations: System Nursing Policy and Procedure This policy was created by incorporating the Committee Northwell Health’s Geriatric Guidelines for Pain Management into the Northwell Health’s Pain Management : Assessment and Reassessment Policy dated 11/10 that can be found on the Intranet. GENERAL STATEMENT of PURPOSE To establish a standard for routine assessment, reassessment and documentation of pain as appropriate to the patient’s condition and treatment regimen. POLICY 1. Patients are screened and assessed for pain based upon clinical presentation, services sought, and in accordance with the care, treatment, and services provided. Facility personnel use methods to assess pain that are consistent with the patient’s age, condition, and ability to understand. 2. If the patient reports pain to a health care worker other than a licensed health care provider, the health care worker will escalate the report of pain to a licensed health care provider for assessment. 3. Pain assessment performed by health care providers will address individual, cultural, spiritual, and language differences. Pain measurement scales are available in various languages and, if necessary, access to a medical interpreter will be provided to assist in the evaluation of the patient’s pain. 4. The patient’s self-report of pain is considered the “gold standard.” For those patients who are unable to communicate the health care provider will assess pain by using the appropriate pain Measurement Scale. -
Employees Calling About RTW Clearance
1. Employee should do home quarantine for 7 days Employees calling and consult their physician about RTW clearance 2. Employee must call their own manager to call in Community/General Exposure OR sick as per their usual policy IP&C or Supervisor Confirmed Exposure 3. To return to work, employee must be fever-free without antipyretic for 3 days (72 hours) AND 1. Confirm that employee symptoms improveD AND finisheD 7-day home has finished 7-day home quarantine Community/General/ Travel/ quarantine AND fever-free Day Zero= First Day of Symptoms without antipyretics for 3 CDC Level 2/3 Country* COVID Permitted work on the 8th day days (72 hours) AND Exposure Employee must call the WHS hotline back symptoms have improved then for RTW clearance Employees who call-in 2. Employee should wear Community/General/ 4.Fill out RTW form to place employee off-duty with non-CLI surgical face mask during Unknown COVID Symptoms, but still entire shift while at work exposure (any not feeling well: going forward 3. If employee has been off- exposure that is NOT Please remember to stay duty for 8 or more calendar “Infection Prevention home if you don’t feel days, then email and Control (IP&C) well. Healthcare team confirmed) [email protected] Personnel must not work with doctor’s note simply sick. Follow usual steps stating that they sought for take sick day and care/treatment for COVID- contact their manager. Note: loss of smell/taste alone does If there are NO like symptoms ANY 4.Employee should update NOT constitute CLI per WHS No RTW form needed for symptoms following their manager COVID-19 Symptoms: guidelines Employees with NO non-CLI exposure or travel, 5. -
Assessment of Pain
ASSESSMENT OF PAIN Pediatric Pain Resource Nurse Curriculum © 2017 Renee CB Manworren, PhD, APRN, FAAN and Ann & Robert H. Lurie Children’s Hospital of Chicago. All rights reserved. Objectives • Critically evaluate pain assessment tools for reliability, validity, feasibility and utility Table of Contents for communicating pediatric patients’ pain experiences • Formulate processes and policies to ensure the organization’s pain assessment and care planning for pediatric patients is sensitive to children’s pain by acknowledging the sensory, cognitive and affective experience of pain and behavioral responses as influenced by social, cultural, spiritual and regulatory context. • Engage in pain assessment demonstrating evidence-based processes, modeling assessment principles, and using valid and reliable tools that are appropriate for the developmental level, cognitive ability, language, and care needs of pediatric patients cared for in your clinical area. page page page page page 3 8 15 17 30 Why Assess Pain in Principles of Pain Pain Assessment Process Initial Assessment Choosing Pain Children? Assessment Assessment Tools page page page page page 35 48 56 63 66 Pain Assessment Tools Assessment of Those Special Populations In Summary References for Self-report Unable to Self-report | 2 Why Assess Pain in Children? Why do you think it is Type your answer here. important to screen for and assess pain in children? | 4 Because… Assessment and treatment of pain is a fundamental human right. Declaration of Montreal , The International Association for the Study of Pain., 2011 Pain in children occurs across a spectrum of conditions including everyday pains, acute injuries and medical events, recurrent or chronic pain, and pain related to chronic or life-limiting conditions. -
Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes
Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes Type 2 Diabetes ranges from predominantly insulin resistant with relative insulin deficiency to predominantly an insulin secretory defect with insulin resistance, American Diabetes Association, 2010. (ICD 9 code 250.0) Prevalence • 23.6 million Americans have diabetes – 7.8% of U.S. population. Of these, 5.7 million do not know they have the disease. • 1.6 million people ≥20 years of age are diagnosed with diabetes annually. • 90–95% of diabetic patients have Type 2 Diabetes. Manifestations Clinical of untreated diabetes • High blood glucose level • Excessive thirst • Frequent urination • Weight loss • Fatigue Oral • Increased risk of dental caries due to salivary hypofunction • Accelerated tooth eruption with increasing age • Gingivitis with high risk of periodontal disease (poor control increases risk) • Salivary gland dysfunction leading to xerostomia • Impaired or delayed wound healing • Taste dysfunction • Oral candidiasis • Higher incidence of lichen planus Other Potential Disorders/Concerns • Ketoacidosis, kidney failure, gastroparesis, diabetic neuropathy and retinopathy • Poor circulation, increased occurrence of infections, and coronary heart disease Management Medication The list of medications below are intended to serve only as a guide to facilitate the dental professional’s understanding of medications that can be used for Type 2 Diabetes. Medical protocols can vary for individuals with Type 2 Diabetes from few to multiple medications. ACTION TYPE BRAND NAME/GENERIC SIDE EFFECTS Enhance insulin Sulfonylureas Glipizide (Glucotrol) Angioedema secretion Glyburide (DiaBeta, Fluconazoles may increase the Glynase, Micronase) hypoglycemic effect of glipizide Glimepiride (Amaryl) and glyburide. Tolazamide (Tolinase, Corticosteroids may produce Diabinese, Orinase) hyperglycemia. Floxin and other fluoroquinolones may increase the hypoglycemic effect of sulfonylureas.